Harnessing Placebo Effects for the Treatment of Functional Cognitive Disorder: A Feasibility Pilot Study.

Functional Neurological Disorder Placebo Effects Rehabilitation (Neuropsychiatric) Sham Stimulation Somatoform Disorders Transcranial Magnetic Stimulation

Journal

The Journal of neuropsychiatry and clinical neurosciences
ISSN: 1545-7222
Titre abrégé: J Neuropsychiatry Clin Neurosci
Pays: United States
ID NLM: 8911344

Informations de publication

Date de publication:
12 Feb 2024
Historique:
medline: 12 2 2024
pubmed: 12 2 2024
entrez: 12 2 2024
Statut: aheadofprint

Résumé

Limited research has directly investigated whether and how placebo effects can be harnessed for the treatment of functional neurological disorder (FND), despite a long-standing and controversial history of interest in this area. A small exploratory study was conducted with adults with a cognitive subtype of FND recruited from a single cognitive neurology center in the United States. Participants were given the expectation of receiving cranial stimulation that could benefit their memory symptoms; however, the intervention was sham transcranial magnetic stimulation (placebo). Outcomes included measures of short-term memory testing, subjective memory rating, and state anxiety before and after stimulation. After the study, the true objective and rationale for investigating placebo effects were explained in a scripted debriefing session. Acceptability of the study design and qualitative feedback were collected. Institutional ethics approval and signed consent were obtained. Three patients (female, N=2; male, N=1; average age=57 years) were recruited. Outcome data were analyzed descriptively at the patient level. Trends of improvement in subjective memory rating, but not objective cognitive test scores, and decreases in state anxiety were observed. After the debriefing session, all patients found the study design to be acceptable (ratings of 70%, 90%, and 100%), and two of the three patients believed that withholding mechanistic information about the intervention was needed to leverage placebo effects as treatment. In the first study to prospectively investigate the feasibility of harnessing placebo effects for the treatment of FND, promising preliminary findings were obtained, and methods and resources for use in larger future studies are offered.

Identifiants

pubmed: 38343313
doi: 10.1176/appi.neuropsych.20230118
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

appineuropsych20230118

Déclaration de conflit d'intérêts

Dr. Perez has received honoraria for continuing medical education lectures; he has received royalties from Springer Nature; he has served on the editorial boards of

Auteurs

Matthew J Burke (MJ)

Neuropsychiatry Program, Department of Psychiatry, and Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto (Burke); Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Burke); Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology (Burke, Cappon, Santarnecchi) and Program in Placebo Studies (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Center for Memory Health, Hebrew SeniorLife, Boston (Cappon, Pascual-Leone); Department of Neurology, Harvard Medical School, Boston (Cappon, Pascual-Leone, Santarnecchi); Departments of Neurology and Psychiatry (Perez) and Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging (Santarnecchi), Massachusetts General Hospital and Harvard Medical School, Boston; Guttmann Brain Health Institute, Barcelona, Spain (Pascual-Leone).

Davide Cappon (D)

Neuropsychiatry Program, Department of Psychiatry, and Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto (Burke); Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Burke); Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology (Burke, Cappon, Santarnecchi) and Program in Placebo Studies (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Center for Memory Health, Hebrew SeniorLife, Boston (Cappon, Pascual-Leone); Department of Neurology, Harvard Medical School, Boston (Cappon, Pascual-Leone, Santarnecchi); Departments of Neurology and Psychiatry (Perez) and Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging (Santarnecchi), Massachusetts General Hospital and Harvard Medical School, Boston; Guttmann Brain Health Institute, Barcelona, Spain (Pascual-Leone).

David L Perez (DL)

Neuropsychiatry Program, Department of Psychiatry, and Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto (Burke); Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Burke); Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology (Burke, Cappon, Santarnecchi) and Program in Placebo Studies (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Center for Memory Health, Hebrew SeniorLife, Boston (Cappon, Pascual-Leone); Department of Neurology, Harvard Medical School, Boston (Cappon, Pascual-Leone, Santarnecchi); Departments of Neurology and Psychiatry (Perez) and Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging (Santarnecchi), Massachusetts General Hospital and Harvard Medical School, Boston; Guttmann Brain Health Institute, Barcelona, Spain (Pascual-Leone).

Alvaro Pascual-Leone (A)

Neuropsychiatry Program, Department of Psychiatry, and Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto (Burke); Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Burke); Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology (Burke, Cappon, Santarnecchi) and Program in Placebo Studies (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Center for Memory Health, Hebrew SeniorLife, Boston (Cappon, Pascual-Leone); Department of Neurology, Harvard Medical School, Boston (Cappon, Pascual-Leone, Santarnecchi); Departments of Neurology and Psychiatry (Perez) and Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging (Santarnecchi), Massachusetts General Hospital and Harvard Medical School, Boston; Guttmann Brain Health Institute, Barcelona, Spain (Pascual-Leone).

Emiliano Santarnecchi (E)

Neuropsychiatry Program, Department of Psychiatry, and Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto (Burke); Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Burke); Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology (Burke, Cappon, Santarnecchi) and Program in Placebo Studies (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Center for Memory Health, Hebrew SeniorLife, Boston (Cappon, Pascual-Leone); Department of Neurology, Harvard Medical School, Boston (Cappon, Pascual-Leone, Santarnecchi); Departments of Neurology and Psychiatry (Perez) and Precision Neuroscience and Neuromodulation Program, Gordon Center for Medical Imaging (Santarnecchi), Massachusetts General Hospital and Harvard Medical School, Boston; Guttmann Brain Health Institute, Barcelona, Spain (Pascual-Leone).

Classifications MeSH